Mesoblast (MESO) Price & Analysis

Compare

896 Followers

MESO Stock Chart & Stats

$17.65

-$0.53(-2.96%)

At close: Jan 08 4:00 PM EST

$17.65

-$0.53(-2.96%)

Day’s Range― - ―

52-Week Range$8.80 - $22.00

Previous CloseN/A

Volume155.35K

Average Volume (3M)221.37K

Market Cap

$2.00B

Enterprise Value$1.35B

Total Cash (Recent Filing)$38.03M

Total Debt (Recent Filing)$126.11M

Price to Earnings (P/E)―

Beta1.27

Next Earnings

Feb 26, 2026

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding128,296,720

10 Day Avg. Volume145,208

30 Day Avg. Volume221,365

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.68

Enterprise Value/Revenue238.47

Enterprise Value/Gross Profit-59.92

Enterprise Value/Ebitda-27.36

Forecast

1Y Price Target

$29.50

Price Target Upside67.14% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Regulatory ProgressThe FDA approval of Ryoncil provides Mesoblast with better-defined requirements for BLA filing, helping streamline development efforts and de-risk future expansion.

Revenue EstimatesMesoblast's early performance with Ryoncil has exceeded expectations, leading to increased revenue estimates and a higher 12-month price target.

Sales GrowthRyoncil gross sales in steroid-refractory acute graft vs. host disease increased to $21.9M in the September quarter, up 66% from the June quarter.

Bears Say

Mesoblast News

Mesoblast Announces Director’s Share Acquisition and New Equity Issuance

An update from Mesoblast ( ($MESO) ) is now available. On October 28, 2025, Mesoblast Limited announced a...

10d ago

MESO

Mesoblast’s Promising Study on Chronic Low Back Pain Treatment: A Market Game Changer?

Mesoblast (($MESO)) announced an update on their ongoing clinical study. Study Overview: Mesoblast is conducting a clinical study...

12d ago

MESO

Mesoblast Reports Strong Revenue Growth with Ryoncil® Adoption

Mesoblast ( ($MESO) ) just unveiled an update. On October 20, 2025, Mesoblast Limited reported a significant increase...

17d ago

MESO

Mesoblast reports Q2 Ryoncil revenue up 66% y/y

Mesoblast (MESO) “announced gross revenue of $21.9 million on Ryoncil (remestemcel-L-rknd) sales for the quarter ended September 30,...

1M ago

MESO

Mesoblast receives J-Code for Ryoncil from Medicare & Medicaid Services

Mesoblast (MESO) announced that a specific Healthcare Common Procedure Coding System J-Code assigned to Ryoncil by United States...

1M ago

MESO

Mesoblast’s U.S. Origin Designation Shields Products from Tariffs

Mesoblast ( ($MESO) ) has shared an announcement. On September 26, 2025, Mesoblast Limited announced that its allogeneic...

1M ago

MESO

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: CEA Industries Inc (BNC)...

1M ago

BNC

MBX

Buy Rating for Mesoblast Driven by Strong Ryoncil Launch and Strategic Financial Moves

Maxim Group analyst Jason McCarthy maintained a Buy rating on Mesoblast yesterday and set a price target of...

2M ago

MESO

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Outlook Therapeutics Inc (OTLK)...

2M ago

LIT

Mesoblast’s Earnings Call Highlights Growth and Challenges

Mesoblast (($MESO)) has held its Q4 earnings call. Read on for the main highlights of the call. The...

2M ago

MESO

Mesoblast falls -12.9%

Mesoblast (MESO) is down -12.9%, or -$2.05 to $13.90. Published first on TheFly – the ultimate source for...

2M ago

MESO

Mesoblast falls -12.5%

Mesoblast (MESO) is down -12.5%, or -$2.00 to $13.95. Published first on TheFly – the ultimate source for...

2M ago

MESO

Mesoblast Limited Reports 2025 Earnings and Strategic Outlook

Mesoblast ( ($MESO) ) has released its Q4 earnings. Here is a breakdown of the information Mesoblast presented...

2M ago

MESO

Mesoblast reports FY25 net loss ($102.1M) vs. ($88.0M) last year

Reports FY25 revenue $17.2M vs. $5.9M last year. Mesoblast (MESO) CEO Dr. Silviu Itescu said, “This has been...

2M ago

MESO

MESO FAQ

What was Mesoblast’s price range in the past 12 months?

Mesoblast lowest stock price was $8.80 and its highest was $22.00 in the past 12 months.

What is Mesoblast’s market cap?

Mesoblast’s market cap is $2.00B.

When is Mesoblast’s upcoming earnings report date?

Mesoblast’s upcoming earnings report date is Feb 26, 2026 which is in 110 days.

How were Mesoblast’s earnings last quarter?

Mesoblast released its earnings results on Aug 28, 2025. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.373 by -$0.057.

Is Mesoblast overvalued?

According to Wall Street analysts Mesoblast’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mesoblast pay dividends?

Mesoblast does not currently pay dividends.

What is Mesoblast’s EPS estimate?

Mesoblast’s EPS estimate is -0.13.

How many shares outstanding does Mesoblast have?

Mesoblast has 128,296,720 shares outstanding.

What happened to Mesoblast’s price movement after its last earnings report?

Mesoblast reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.373. Following the earnings report the stock price went down -13.292%.

Which hedge fund is a major shareholder of Mesoblast?

Currently, no hedge funds are holding shares in MESO

Mesoblast Stock Smart Score

Neutral

Fundamentals

Return on Equity

-18.96%

Trailing 12-Months

Asset Growth

17.27%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mesoblast

Mesoblast Limited (NASDAQ: MESO) is a global leader in developing innovative cellular medicines. The company focuses on regenerative medicine, specifically the use of adult stem cells to treat various diseases and conditions, including heart disease, chronic lower back pain, and inflammatory conditions. Mesoblast's proprietary technology platforms enable the development of products that leverage the unique properties of mesenchymal stem cells (MSCs) to promote healing and repair in damaged tissues.

Mesoblast (MESO) Earnings & Revenues

Historic Earnings Reports

MESO Company Deck

MESO Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call illustrated significant growth and successful product launch achievements, particularly with Ryoncil's market penetration and FDA approval. However, increased operational expenses and revaluation-related losses presented financial challenges. Overall, the company's positive strides in market access and regulatory feedback indicate strong potential for future growth.View all MESO earnings summaries

MESO Stock 12 Month Forecast

Average Price Target

$29.50

▲(67.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","36":"$36","14.25":"$14.25","21.5":"$21.5","28.75":"$28.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,14.25,21.5,28.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.27,17.71076923076923,19.15153846153846,20.592307692307692,22.033076923076923,23.473846153846154,24.914615384615384,26.355384615384615,27.796153846153846,29.236923076923077,30.677692307692308,32.11846153846154,33.559230769230766,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.27,17.287692307692307,18.305384615384614,19.323076923076922,20.34076923076923,21.358461538461537,22.376153846153848,23.393846153846155,24.411538461538463,25.42923076923077,26.446923076923078,27.464615384615385,28.482307692307693,{"y":29.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.27,16.864615384615384,17.459230769230768,18.053846153846152,18.64846153846154,19.243076923076924,19.837692307692308,20.432307692307692,21.026923076923076,21.621538461538464,22.216153846153844,22.810769230769232,23.405384615384616,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.72,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.14,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.94,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.38,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.12,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":15.17,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >